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Angiopoietin-1 is an important regulator of endothelial cell survival. Angiopoietin-1 also reduces vascular permeability
mediated by vascular endothelial growth factor. The effects of angiopoietin-1 on tumour growth and angiogenesis are
controversial. We hypothesised that angiopoietin-1 would decrease tumour growth and ascites formation in peritoneal
carcinomatosis. Human colon cancer cells (KM12L4) were transfected with vector (pcDNA) alone (control) or vector
containing angiopoietin-1 and injected into the peritoneal cavities of mice. After 30 days, the following parameters were
measured: number of peritoneal nodules, ascites volume, and diameter of the largest tumour. Effects of angiopoietin-1 on
vascular permeability were investigated using an intradermal Miles assay with conditioned media from transfected cells. Seven
of the nine mice in the pcDNA group developed ascites (1.3+0.5 ml (mean+s.e.m.)), whereas no ascites was detectable in
the angiopoietin-1 group (0 out of 10) (P50.01). Number of peritoneal metastases (P50.05), tumour volume, (P50.05),
vessel counts (P50.01), and tumour cell proliferation (P50.01) were signiﬁcantly reduced in angiopoietin-1-expressing
tumours. Conditioned medium from angiopoietin-1-transfected cells decreased vascular permeability more than did
conditioned medium from control cells (P50.05). Our results suggest that angiopoietin-1 is an important mediator of
angiogenesis and vascular permeability and thus could theoretically serve as an anti-neoplastic agent for patients with
carcinomatosis from colorectal cancer.
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Angiogenesis has been associated with aggressive disease in human
colorectal cancer (Takahashi et al, 1995, 1998). Although the vascular
endothelial growth factor (VEGF) receptor-ligand system has been
implicated as a critical mediator of vasculogenesis and angiogenesis,
the angiopoietins (Ang-1 to Ang-4) have also been shown to be
important regulators of neovascularisation and endothelial cell survi-
val in malignant and non-malignant tissues (Peters, 1998). Ang-1 has
been recognised as the major ligand that activates the tyrosine kinase
receptor Tie2, thereby promoting endothelial cell survival and vessel
stabilisation by recruiting and sustaining peri-endothelial supporting
cells (Fujikawa et al, 1999; Hayes et al, 1999; Kwak et al, 1999; Papa-
petropoulos et al, 1999). Ang-2 is the naturally occurring antagonist
to Ang-1; Ang-2 prevents Tie2 activation and results in vessel desta-
bilisation (Maisonpierre et al, 1997). Studies in transgenic mice
revealed that inactivation of Ang-1 or the Tie2 receptor causes
embryos to die from defects in vascular remodelling (Dumont et al,
1994; Sato et al, 1995; Suri et al, 1996). Recently, studies have shown
that the angiopoietins are sequentially expressed during the angio-
genic process, indicating that they are also important modulators
of post-natal neovascularisation. Balanced and sequential expression
of the angiopoietins and VEGF is required for successful angiogenesis
(Asahara et al, 1998; Ray et al, 2000). In addition, Ang-1 has been
shown to override VEGF-mediated effects on vascular permeability
(vessel leakage) of adult vasculature (Thurston et al, 1999, 2000).
The effects of the angiopoietins on angiogenesis, tumour growth
and vascular permeability remain controversial (Suri et al, 1998;
Chae et al, 2000; Hayes et al, 2000; Ahmad et al, 2001; Shim et
al, 2001). Some studies suggest that Ang-1 may be pro-angiogenic
(Suri et al, 1998; Hansbury et al, 2001; Shim et al, 2001), whereas
others have shown that Ang-1 inhibits angiogenesis, tumour
growth and vascular permeability (Chae et al, 2000; Hayes et al,
2000; Thurston et al, 2000; Ahmad et al, 2001; Tian et al, 2002).
We hypothesised that overexpression of Ang-1 by human colon
cancer cells would decrease angiogenesis, tumour growth and metas-
tasis formation and inhibit ascites formation in an experimental
model of peritoneal carcinomatosis. Our results suggest that Ang-
1 is an important regulator of angiogenesis and vascular permeabil-
ity and thus indicate that Ang-1 could theoretically serve as an anti-
angiogenic agent in the treatment of metastatic colorectal cancer.
MATERIALS AND METHODS
Cell culture and transfection
The highly metastatic human colon cancer cell line KM12L4 was
obtained from IJ Fidler (The University of Texas M.D. Anderson
Cancer Center) (Morikawa et al, 1988). KM12L4 cells were
cultured and maintained on plastic in modiﬁed Eagle’s medium
supplemented with 10% foetal bovine serum, 2 units ml
71 penicil-
lin–streptomycin mixture (Flow Laboratories, Rockville, MD,
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Received 2 May 2002; revised 5 August 2002; accepted 19 August 2002
*Correspondence: Dr LM Ellis, Department of Surgical Oncology, Box 444,
The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, TX 77030-4009, USA; E-mail: lellis@mdanderson.org
British Journal of Cancer (2002) 87, 1182–1187
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comUSA), two-fold vitamin solution (Life Technologies, Inc., Grand
Island, NY, USA), 1 mM sodium pyruvate, 2 mM L-glutamine
and non-essential amino acids and incubated in 5% CO2–95%
air at 378C as previously described (Shaheen et al, 2001).
The full-length cDNA for Ang-1 was provided by Tona Gilmer
(GlaxoSmithKline, Research Triangle Park, NC, USA). The
construct was sub-cloned into a pcDNA3 vector (InVitrogen,
Carlsbad, CA, USA) containing a hygromycin resistance gene
(Ahmad et al, 2001). Vector alone or vector containing Ang-1
was transfected into KM12L4 cells using Lipofectin according to
the manufacturer’s protocol (Boehringer Mannheim Co., Rand-
burg, South Africa), and the transfected cells were grown in
selective media as previously described (Ahmad et al, 2001).
Successful transfection of Ang-1 was conﬁrmed by Northern blot
analysis as previously described (Ahmad et al, 2001).
For in vivo studies, Ang-1- and pcDNA-transfected KM12L4
cells were harvested from sub-conﬂuent cultures. Brieﬂy, cells were
rinsed with phosphate-buffered saline (PBS), trypsinised (0.25%
trypsin; 0.02% EDTA) and re-suspended in 10% foetal bovine
serum–modiﬁed Eagle’s medium. Cells were counted and cell
viability was assessed using the Trypan blue dye exclusion assay
(490% viability). Cells were resuspended in Hank’s balanced salt
solution for tumour cell inoculation into mice.
In vivo studies
Eight-week-old male athymic nude mice (obtained from the
Animal Production Area of the National Cancer Institute and
Development Center, Frederick, MD, USA) were acclimated for
1–2 weeks while caged in groups of ﬁve. Mice were housed as
previously described (Shaheen et al, 2001) and fed a diet of animal
chow and water ad libitum throughout the experiment. Experi-
ments were approved by the Animal Care and Use Committee at
M. D. Anderson Cancer Center and met all the standards required
by the UKCCCR guidelines for the welfare of animals in experi-
mental neoplasia, as published (United Kingdom Co-Ordinating
Committee on Cancer Research, 1998).
Peritoneal carcinomatosis model Mice were randomly assigned
to one of two groups (n=10 per group). The average body weight
among groups was similar at assignment. Under sterile conditions,
either Ang-1- or pcDNA (control)-transfected KM12L4 cells
(1610
6 cells) were injected into the peritoneal cavity of each mouse
by means of a 30-gauge needle. An injection volume of 500 ml (in
Hank’s balanced salt solution) was used to achieve a distribution
adequate for peritoneal implantation of tumour cells. Animals were
monitored daily (weighed once per week), and when mice in any
group showed early signs of decreased mobility, all animals were
killed by cervical dislocation after anaesthesia induction with pento-
barbital (Nembutal, 50 mg kg
71). Body weight was determined, and
ascites was collected by performing a lower midline incision and
completely draining the intra-abdominal ﬂuid into a ﬂask. The
ascites volume was then measured with a 1-ml tuberculin syringe.
Incisions were then extended to allow photography of the peritoneal
cavity and determination of the extent of peritoneal carcinomatosis.
Peritoneal tumour nodules were counted, and the diameter of the
largest tumour (always occurring in the greater omentum) was
determined. Tumour tissue was then harvested, placed in either
10% formalin for parafﬁn embedding or snap-frozen in optimum
cutting temperature solution (Miles Inc., Elkhart, IN, USA) in
preparation for subsequent immunohistochemical analyses.
Intradermal Miles assay To investigate the effects of overexpres-
sion of Ang-1 by tumour cells on vascular permeability, the
intradermal Miles assay was performed as described previously
(Zebrowski et al, 1999). Conditioned medium (CM) from Ang-1-
and pcDNA-transfected KM12L4 cells was collected after a 48-h
incubation in 5% foetal bovine serum–modiﬁed Eagle’s medium
at 80% cell density, centrifuged for 5 min at 2000 r.p.m. and ﬁltered
through a 0.22-mm ﬁlter. Mice (n=3 per group) were injected intra-
venously with sterile 0.5% Evans blue dye (200 ml) via the tail vein.
Ten minutes later, mice were given four separate intradermal injec-
tions at different sites into the dorsal skin – one each of CM-Ang-1,
CM-pcDNA, PBS (negative control), and PBS plus VEGF
(10 ng ml
71) (R&D Systems Inc., Minneapolis, MN, USA) (positive
control for increased vascular permeability). The injections were
done using a 30-gauge needle, and the injection volume was
50 ml. Mice were sacriﬁced 20 min after intradermal injections by
cervical dislocation following anaesthesia induction with nembutal.
The dorsal skin of each mouse was harvested to permit visualisation
of intradermal dye leakage. To determine the relative degree of
vascular permeability, two dimensions (a and b) of the elliptically
appearing area of dye leakage were obtained at each injection site
and the area was calculated by the formula a6b6p. Densitometric
analysis was performed using the NIH Image Analysis software
(V1.62) from the National Institute of Health (Bethesda, MD,
USA) as another means of quantifying the extent of dye leakage
at the intradermal injection sites in each mouse. Digitally obtained
images of the underside of the dorsal skin, including all injection
sites, were converted to a gray-scale image, and dye density was
analysed at each site (threshold was set individually for each dorsal
skin ﬂap, but was constant for each mouse).
Immunohistochemical analyses of tumour vessel density
Antibodies for immunohistochemical analyses were obtained as
follows: rat anti-mouse CD31 antibody from PharMingen (San
Diego, CA, USA) and peroxidase-conjugated goat anti-rat IgG from
Jackson Research Laboratories (West Grove, PA, USA). Tumours
that had been frozen in optimum cutting temperature solution
were sectioned at 8-mm intervals, mounted on positively charged
slides and air-dried for 30 min. Tissue sections were then ﬁxed
in cold acetone, followed by 1:1 acetone/chloroform and acetone,
and then washed with PBS. Specimens were then incubated with
3% H2O2 in methanol for 12 min at room temperature to block
endogenous peroxidase, washed with PBS (pH 7.5) and incubated
for 20 min at room temperature in a protein-blocking solution
consisting of PBS supplemented with 1% normal goat serum and
5% normal horse serum. The primary antibody directed against
CD31 was diluted 1:800 in protein-blocking solution and applied
to the sections, which were incubated overnight at 48C. Sections
were then rinsed in PBS and incubated for 10 min in protein-
blocking solution before the addition of peroxidase-conjugated
secondary antibody. The secondary antibody used for CD31 stain-
ing (peroxidase-conjugated goat anti-rat IgG) was diluted 1:200 in
protein-blocking solution. After incubation with the secondary
antibody for 1 h at room temperature, the samples were washed
and incubated with stable diaminobenzidine substrate (Research
Genetics, Huntsville, AL, USA). Staining was monitored under a
bright-ﬁeld microscope, and the reaction was stopped by washing
with distilled water. Sections were counterstained with Gill No. 3
haematoxylin solution (Sigma Chemical Co., St. Louis, MO,
USA) and mounted with Universal Mount (Research Genetics).
CD31-stained vessels were counted at 506 magniﬁcation at four
different quadrants of each tumour (2 mm inside the tumour–
normal tissue interface), and average vessel counts were calculated.
For all immunohistochemical procedures, the primary antibody
was omitted as a negative control.
Immunohistochemical analyses of tumour cell
proliferation
Parafﬁn-embedded tumours were sectioned at 4- to 6-mm intervals,
mounted on positively charged Superfrost slides (Fisher Scientiﬁc
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temperature. Sections were deparafﬁnised in xylene, treated with
a graded series of alcohol washes (100, 95, and 80% ethanol in
double-distilled H2O( v v
71)), rehydrated in PBS (pH 7.5) and
microwaved for 5 min for antigen retrieval. Tumour sections were
stained for proliferating cell nuclear antigen (PCNA) using mouse
anti-PCNA clone PC10 DAKO A/S (DAKO Corp., Carpinteria, CA,
USA). Immunohistochemical procedures were performed as
described previously (Ahmad et al, 2001). Positive reactions were
visualised by incubating the slides with stable diaminobenzidine
for 10–20 min. The sections were rinsed with distilled water,
counterstained with Gill No. 3 haematoxylin solution for 1 min,
and mounted with Universal Mount. The number of tumour cells
staining and not staining for PCNA was determined (at 1006
magniﬁcation) at four staining ‘hot spots’ per tumour sample,
and the percentage of PCNA-positive cells was then calculated.
Necrotic areas of the tumour were excluded. Slides were also
stained with haematoxylin and eosin to permit study of overall
tissue morphology.
Statistical analyses
All statistical analyses were done using InStat Statistical Software
version 2.03 (GraphPad Software, San Diego, CA, USA), with P
values less than 0.05 considered to be statistically signiﬁcant.
Tumour-associated parameters were tested for statistical signiﬁcance
using the two-sided Student’s t-test or Mann–Whitney U-test (for
non-parametric data). Fisher’s exact test was applied for comparing
incidences of peritoneal carcinomatosis and ascites formation.
RESULTS
Effect of angiopoietin-1 expression on formation of
peritoneal metastases and tumour growth
To study the effect of Ang-1 on peritoneal implantation and
growth of human colon cancer cells, pcDNA- and Ang-1-trans-
fected KM12L4 cells were injected into the peritoneal cavities of
nude mice. Thirty days after tumour cell inoculation, three of
the control (pcDNA) mice showed decreased mobility (secondary
to ascites), and the experiment was terminated. (One mouse in
the pcDNA group died at day 21 of acute bowel obstruction caused
by a peritoneal tumour). Peritoneal carcinomatosis developed in
seven (78%) of the nine mice in the control group, compared to
three (30%) of the 10 mice of the Ang-1 group. However, the inci-
dences of development of carcinomatosis were not signiﬁcantly
different (P=0.07).
To evaluate the effects of Ang-1 overexpression on tumour
burden in mice, the number of peritoneal metastases and the
volume of the largest tumour (occurring in the greater omentum)
were calculated for each mouse. The total number of peritoneal
metastases was signiﬁcantly lower in the Ang-1 group than in the
control group (P50.01) (Figure 1A). Peritoneal nodules were
additionally categorised into size ranges (greatest diameter), as a
more precise volume measurement (cubic mm) was not feasible
due to their abundance. Small tumours (1–5 mm) were detectable
at frequency of 2.2+1.4 nodules/mouse (mean +s.e.m.)) in the
pcDNA group and a mean of 0.3+0.2 nodules/mouse in the
Ang-1 group (P50.05). Large tumours (6–15 mm) were detect-
able at frequency of 13.4+3.3 nodules/mouse in the pcDNA
group and compared to 0.5+0.3 nodules/mouse in the Ang-1
group (0.5+0.3) (P50.05). As tumour growth beyond 1–2 mm
is angiogenesis dependent, measurement of the largest tumour
was a consistent and unbiased reﬂection of the effects of Ang-1
on tumour angiogenesis. The maximal tumour volume was signiﬁ-
cantly less in the Ang-1 group than in the pcDNA group (P50.05)
(Figure 1B).
Effect of angiopoietin-1 expression on ascites formation
The incidence of ascites formation was signiﬁcantly higher in
mice injected with pcDNA-transfected KM12L4 cells (7 out of
9, 78%) than in mice injected with Ang-1-overexpressing
KM12L4 cells (0 out of 10) (P50.01, Fisher’s exact test). The
ascites volumes in peritoneal metastases–bearing mice in the
pcDNA group ranged from 0.3 ml to 5 ml, with a median ascites
volume of 1.3 ml (haemorrhagic ascites in all cases). The median
ascites volume was signiﬁcantly higher in the pcDNA group
(P50.01) than in the Ang-1 group as none of the Ang-1 mice
developed ascites even though three of them had peritoneal
tumours (Figure 2).
Effect of angiopoietin-1 expression on microvessel density
and tumour cell proliferation
To determine the effects of Ang-1 overexpression on tumour
neovascularisation and tumour cell proliferation, peritoneal metas-
tases were sectioned and evaluated by immunohistochemical
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Figure 1 Effect of Ang-1 overexpression on tumour growth. Ang-1- or
pcDNA-transfected KM12L4 colon cancer cells were injected into the
peritoneal cavities of mice. (A) After 30 days, mice were killed and peri-
toneal metastases were counted. Overexpression of Ang-1 in colon can-
cer cells signiﬁcantly reduced the number of peritoneal metastases
(P50.01, Mann–Whitney U-test) compared to controls (pcDNA). Bars:
median. (B) The largest tumour (greater omentum) was measured in
each mouse. Tumour volumes in the Ang-1 group were signiﬁcantly smal-
ler than tumours in the pcDNA group (P50.05, Mann–Whitney U-test).
Bars: s.e.m.
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transfected KM12L4 tumours relative to controls (pcDNA)
(P50.01) (Figures 3A and 4). In addition, analysis of PCNA
immunohistochemical staining revealed that Ang-1-overexpressing
tumours had a signiﬁcantly lower percentage of proliferating
tumour cells in peritoneal metastases compared to control tumours
(P50.01) (Figures 3B and 4).
Effect of angiopoietin-1 expression on vascular
permeability
To demonstrate whether the observed inhibition of ascites forma-
tion was attributable to reduced vascular permeability mediated by
Ang-1 and not solely dependent on tumour burden, we used the
Miles in vivo permeability assay to determine the direct effect of
Ang-1 on vascular permeability. In this assay, effects on vascular
permeability were investigated using conditioned media from
Ang-1- or pcDNA-transfected KM12L4 cells. Injections with PBS
and PBS plus VEGF served as a negative and positive control,
respectively. Areas of intradermal dye leakage (a measure of vascu-
lar permeability) were signiﬁcantly smaller at CM-Ang-1 injection
sites than at CM-pcDNA injection sites (or PBS-plus-VEGF injec-
tion sites, the positive control) (P50.05) (Figure 5). All injection
sites were additionally analysed by densitometry to verify these
results. Dye density at CM-Ang-1 sites (39.4+8.2 pixels
2610
3
(mean+s.e.m.)) was signiﬁcantly lower compared to CM-pcDNA
sites (76.8+2.9 pixels
2610
3)( P50.01, Student’s t-test).
DISCUSSION
In the present study, overexpression of Ang-1 by human colon
cancer cells inhibited tumour angiogenesis, growth of peritoneal
metastases and ascites formation in an experimental model of peri-
toneal carcinomatosis. In studies using the HT29 human colon
cancer cell line transfected with Ang-1, similar growth-inhibitory
results were obtained (data not shown).
The effect of Ang-1 on tumour neovascularisation and growth is
controversial. The concept that the angiopoietins are important
mediators of tumour growth was elegantly demonstrated by Holash
and associates, who demonstrated the importance of the coordi-
nated induction of the angiopoietins and VEGF in tumour
angiogenesis (Holash et al, 1999). Other studies have suggested that
Ang-1 may be pro-angiogenic. Shim et al (2001) recently demon-
strated that overexpression of antisense Ang-1 mRNA by HeLa
cells inhibited angiogenesis and xenografted tumour growth in
immunodeﬁcient mice. An increased neovascularisation effect by
Ang-1 overexpression was also described by Suri et al (1998) using
a transgenic mouse model. These authors concluded that Ang-1
could be used in combination with VEGF to promote therapeutic
angiogenesis.
The importance of the cooperation of Ang-1 and VEGF in
induction of angiogenesis has been demonstrated in several malig-
nant and non-malignant models of angiogenesis (Peters, 1998; Ray
et al, 2000). In a transgenic mouse model with increased co-expres-
sion of Ang-1 and VEGF, angiogenesis was also increased
(Thurston et al, 1999). This phenomenon of an enhanced vasculo-
genesis by combining Ang-1 with VEGF was also demonstrated by
Chae et al (2000). Using a rabbit ischaemic hind-limb model, they
demonstrated that a combination of Ang-1 and VEGF gene deliv-
ery resulted in the formation of larger blood vessels, increased
blood ﬂow and higher capillary density than was seen when either
factor was delivered alone.
In contrast, several studies suggest that Ang-1 may inhibit
tumour angiogenesis. In our previous studies, we were able to
demonstrate that imbalances in Ang expression may regulate
growth and angiogenesis of human colon cancer (Ahmad et al,
2001). In a subcutaneous xenografted colon cancer model, differen-
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Figure 2 Impact of Ang-1 expression on ascites formation in peritoneal
carcinomatosis. Thirty days after tumour cell inoculation, ascites volumes
were measured in each mouse. Seven of the nine mice in the pcDNA
group developed detectable ascites, with a median ascites volume of
1.3 ml. In contrast, none of the 10 mice in the Ang-1 group developed as-
cites (P50.01, Fisher’s Exact test). Bars: median.
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Figure 3 Effect of Ang-1 overexpression on tumour vessel density and
tumour cell proliferation. (A) Tumour vessels were stained for CD31,
and vessel counts were performed as described in Materials and Methods.
Vessel counts in Ang-1 tumours were signiﬁcantly lower than vessel counts
in pcDNA tumours (*P50.01, two-sided Student’s t-test). (B) In addition,
the percentage of proliferating tumour cells identiﬁed by PCNA staining
was signiﬁcantly reduced in Ang-1-overexpressing tumours (*P50.01,
two-sided Student’s t-test). Bars: s.e.m. HPF, high-power ﬁeld.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1182–1187tial expression of angiopoietins affected both tumour growth and
angiogenesis. Ang-1 overexpression signiﬁcantly inhibited tumour
growth and angiogenesis in this model (Ahmad et al, 2001). These
ﬁndings are now supported by the results of a recent study by Tian
et al (2002), who found that Ang-1 overexpression by MCF-7
breast cancer cells resulted in stabilisation of tumour edge-asso-
ciated blood vessels. In addition, tumour cell proliferation
decreased signiﬁcantly in the presence of Ang-1, resulting in a
reduced xenografted tumour growth. Tie2 receptor was found to
be present in vascular smooth muscle cells in culture in addition
to endothelial cells. On the basis of these results, Tian et al
(2002) concluded that vascular stabilisation by Ang-1 accounts
for the inhibition of tumour growth. In a previous study, Hayes
et al (2000) also demonstrated that Ang-1 overexpression in
MCF-7 human breast cancer cells caused a signiﬁcant retardation
in tumour growth despite the high co-expression of a potent
angiogenic growth factor (ﬁbroblast growth factor-1).
The results of our present study suggest that the effects of Ang-1
on tumour growth were mediated by inhibition of tumour angio-
genesis and that the abrogation of ascites formation was due to a
reduction of vascular permeability (plasma leakage). In this model,
Ang-1 overexpression did not prevent peritoneal implantation of
tumours, although peritoneal nodules were fewer and smaller in
the Ang-1 group. Therefore, Ang-1 prevented angiogenesis depen-
dent tumour outgrowth by inhibiting neovascularisation, which
was reﬂected by measurement of the largest tumour in mice.
As demonstrated in our permeability assay, Ang-1 levels in CM
from Ang-1-transfected cells abrogated the increase of plasma
leakage (dye leakage) of dermal microvasculature caused by
tumour cell–derived growth factors (KM12L4 cells express rela-
tively high amounts of VEGF (Ellis et al, 1996)), suggesting that
Ang-1 is an important mediator of vascular stabilisation and
permeability and may override VEGF-mediated vessel leakage.
Other factors might have been present in conventional medium
or conditioned medium that was used in this assay that poten-
tially might have affected vascular permeability. However, VEGF
is known as the strongest inducer of vascular leakage (Dvorak,
2000; Dvorak et al, 1999). Therefore, although possible, it is unli-
kely that ingredients of conventional medium and factors besides
VEGF played a signiﬁcant role in this assay. This hypothesis is
supported by the results of other groups who have investigated
the effects of Ang-1 on vascular permeability and vessel stabilisa-
tion. Gamble et al (2000) showed that administration of
recombinant Ang-1 supported the localisation of a cell adhesion
molecule (PECAM-1) into junctions between endothelial cells,
strengthening these junctions. In addition, basal permeability of
endothelial cell monolayers was reduced in a dose-dependent
manner by treatment with recombinant Ang-1, and endothelial
cell permeability responses to permeability-inducing agents such
as thrombin and VEGF were inhibited by treatment with Ang-1.
Thurston et al (1999) have reported anti-permeability properties
of Ang-1 in two different studies evaluating the impact of VEGF
on plasma leakage of adult vasculature and in a previous experi-
ment using a transgenic mouse model overexpressing both Ang-1
and VEGF. In the latter study, co-expression of Ang-1 and VEGF
had an additive effect on angiogenesis but resulted in the forma-
tion of leakage-resistant vessels. Furthermore, the authors showed
that acute administration of Ang-1 protected adult vasculature
from leakage mediated by VEGF and inﬂammatory cytokines
(Thurston et al, 2000).
In conclusion, our study indicates that Ang-1 was an important
mediator of tumour angiogenesis and vascular permeability in an
experimental model of peritoneal carcinomatosis from human
colon cancer. The inhibition of vascular permeability by Ang-1 is
especially relevant in a tumour system associated with a great deal
of morbidity due to ascites formation that accompanies carcinoma-
tosis. Our studies suggest that Ang-1 could potentially serve as an
anti-angiogenic/anti-permeability agent in the treatment of carci-
nomatosis from colorectal cancer.
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Figure 4 Immunohistochemical analysis of tumour vessel density (CD31)
and tumour cell proliferation (PCNA) in peritoneal tumours. Tumour sec-
tions were stained with haematoxylin and eosin (H&E), anti-CD31 antibody
or PCNA antibody as described in Materials and Methods. Images were ob-
tained at 506 (H&E, CD31) or 1006 (PCNA) magniﬁcation.
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Figure 5 Effect of Ang-1 overexpression by tumour cells on dermal vas-
cular permeability. Effects on vascular permeability were examined using
the Miles in vivo permeability assay. CM from Ang-1- or pcDNA-trans-
fected cells was injected into the dermis of mice. After 20 min, mice were
killed, and the areas of dye leakage (as a measure of permeability) were
calculated for each injection site. PBS and PBS plus VEGF (10 ng ml
71)
served as negative and positive controls, respectively. In contrast to CM
of pcDNA-transfected cells, Ang-1-containing CM did not increase plasma
leakage, indicating that Ang-1 abrogated permeability effects of tumour
cell–derived growth factors in CM (*P50.05, two-sided Student t-test).
Bars: s.e.m.
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